BioNTech (NasdaqGS:BNTX) has drawn fresh attention after a recent price move, with the stock closing at US$118. Investors are weighing that level against the company’s reported annual revenue growth and current net loss.

The recent 11.78% 1 day share price return and 28.02% 30 day share price return suggest momentum has picked up again, although the 3 year total shareholder return of 17.33% decline shows a tougher longer term picture.

If BioNTech’s move has you thinking about opportunities in the sector, it could be a useful moment to scan healthcare stocks for other healthcare names catching renewed interest.

With the shares at US$118, a reported annual revenue growth rate of 0.96%, a net loss of US$571.6m, and a value score of 1, is this a mispriced biotech opportunity, or is the market already factoring in future growth?

Price to sales of 8x: Is it justified?

At around US$118 per share, BioNTech is trading on a P/S of 8x, which points to a richer valuation than several peers using this yardstick.

The P/S ratio compares the company’s market value to its revenue. This measure is often used for biotech names that are currently loss making or have volatile earnings. With BioNTech reporting approximately US$3.15b in revenue and a net loss of US$571.6m, focusing on sales rather than profits is a common way investors benchmark the current share price.

Against the broader US Biotechs industry, BioNTech’s 8x P/S sits below the sector average of 11.4x. This suggests the market is applying a lower revenue multiple than it does for the typical peer. However, that 8x level is above the peer group average of 5.5x indicated in the data, pointing to a premium versus a closer peer set. Compared with an estimated fair P/S of 6.1x, the current ratio is also higher. Some investors may see this as a gap that could potentially narrow toward that fair level over time if expectations change.

Result: Price-to-sales of 8x (OVERVALUED)

However, the current net loss of US$571.6m and a value score of 1 leave little margin for error if sentiment around the biotech pipeline shifts.

Build Your Own BioNTech Narrative

If you see the numbers differently or prefer to work from your own assumptions, you can build a personalised view of BioNTech in just a few minutes: Do it your way.

Prefer to form your own view? Our platform makes it easy to explore a stock's fundamentals and create your own narrative in minutes.

Looking for more investment ideas?

If BioNTech has caught your eye, do not stop there. Use the Simply Wall St Screener to surface fresh ideas that could sharpen your next move.

• Spot potential bargains early by checking out these 881 undervalued stocks based on cash flows that may be pricing in more caution than their cash flows suggest.
• Ride powerful technology shifts by reviewing these 23 AI penny stocks that are building real businesses around artificial intelligence.
• Add an income angle to your watchlist with these 13 dividend stocks with yields > 3% that offer yields above 3% alongside established dividend records.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.